DGKI抗体;DGKI Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13136(DGKI Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13136(DGKI Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of DGKI Antibody**

The diacylglycerol kinase iota (DGKI) enzyme, encoded by the *DGKI* gene, belongs to the diacylglycerol kinase (DGK) family, which catalyzes the conversion of diacylglycerol (DAG) to phosphatidic acid (PA). Both DAG and PA are critical lipid secondary messengers involved in cellular signaling pathways regulating cell growth, differentiation, and apoptosis. DGKI, specifically, is a type IV DGK isoform characterized by its unique structural domains, including a pleckstrin homology (PH) domain and a sterile alpha motif (SAM), which facilitate membrane association and protein-protein interactions.

DGKI is predominantly expressed in the brain, testis, and immune cells, and it plays roles in neuronal development, T-cell receptor signaling, and membrane trafficking. Dysregulation of DGKI has been implicated in neurological disorders, autoimmune diseases, and cancer. DGKI antibodies are immunological tools designed to detect and quantify DGKI protein levels in research settings. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study DGKI's expression patterns, subcellular localization, and functional mechanisms in disease models. Recent studies also explore DGKI as a potential therapeutic target or biomarker, particularly in contexts where lipid signaling pathways are disrupted. These antibodies aid in elucidating DGKI's contribution to cellular homeostasis and pathological processes.